Pipeline
We are developing best-in-class copper-based therapeutics and companion diagnostics. Our pipeline comprises tumor indications with high medical need where our copper-based radiopharmaceuticals show a great potential for superior performance.
Program
Indication
Discovery
Preclinical
Phase 1
NuriPro ™
Prostate Cancer
TraceNET ™
Neuroendocrine
Tumours (NET)
CuNeo ™
Colorectal, Gastric &
Lobular Breast Cancer
Kalios ™
Ductal Breast & Lung
Cancer
AlphaFlare ™
Head & Neck
Pancreatic Cancer
Diagnostic (61Cu-X)
Therapeutic (67Cu-X)
NutriPro ™
Prostate Cancer
Discovery Preclinical Phase 1
61Cu-PSMA
67Cu-PSMA
TraceNET ™
Neuroendocrine Tumours (NET)
Discovery Preclinical Phase 1
61Cu-SSTR
67Cu-SSTR
Kalios ™
Breast & Lung Cancer
Discovery Preclinical Phase 1
61Cu-FAPI
67Cu-FAPI
AlphaFlare ™
Head & Neck Pancreatic Cancer
Discovery Preclinical Phase 1
61Cu-Integrin
67Cu-Integrin
Diagnostic (61Cu-X)
Therapeutic (67Cu-X)
1 in 8 men will be diagnosed with prostate cancer during their lifetime; 6 out of 10 cases are diagnosed in men 65 or older. The 5-year survival rate for local/regional cancer is 100% but drops drastically to 31% for metastatic cancer. Expression of the Prostate-Specific Membrane Antigen (PSMA) is up to 80 times higher in almost all prostate carcinoma tumours compared to healthy cells. NuriProTM binds specifically to PSMA, enabling precise diagnosis and targeted treatment. Our 61Cu-based NuriProTM diagnostic component enables a technique called delayed imaging, where even smallest metastases can be detected. Based on these imaging data, our 67Cu-based NuriProTM therapeutic can enable targeted treatment with an improved safety and efficacy profile and reduced radiation burden for the patient.
Neuroendocrine tumours (NETs) are rare tumours that develop in cells of the neuroendocrine system. Spread throughout the body, neuroendocrine cells can receive neuronal input like nerve cells (neurons) and, as a consequence of this input, produce and release hormones like cells of the endocrine system (endocrine cells). They are mainly found scattered in the gastrointestinal (GI) tract (including the small intestine, rectum, stomach, colon, esophagus, and appendix), the gallbladder, the pancreas (islet cells) and the thyroid (C cells). NETs are difficult to detect and are usually found at an advanced stage. Like prostate cancer, the survival rate significantly drops the more advanced or metastasised the tumor is (5-year survival for metastatic pancreatic NETs: 24 %) Our TraceNETTM program targets somatostatin receptors, which are a clinically validated NET cell marker. Our 61Cu-based TraceNETTM diagnostic component is highly precise and enables a technique called delayed imaging, where even smallest tumours can be detected early. Based on these imaging data, our 67Cu-based TraceNETTM therapeutic can enable targeted treatment with an improved safety and efficacy profile and reduced radiation burden for the patient.
80 – 90% of all cancer cases are of epithelial origin, stemming from cells in the internal and external lining of the body. KaliosTM is targeting cells in the tumor microenvironment called cancer-associated fibroblasts, which are present in epithelial tumours such as breast and lung cancer and are not present in healthy tissues. Early detection of metastases in lymph nodes and crucial organs can increase the survival rate through early intervention. Unlike other tracers, our 61Cu-based KaliosTM diagnostic component can be used effectively in staging to detect nodal metastases in the liver and peritoneum.
CuNeoTM is addressing a novel cancer target that is critically involved in cancer cell migration, invasion and metastasis formation, which represent the major cause of cancer related deaths. It has been shown to be upregulated in high need solid tumour indications such as colorectal cancer, gastric cancer and lobular breast cancer. Diagnostic imaging with CuNeoTM’s 61Cu-component allows for the early detection of nodal and distant metastases (correct staging), enabling a highly personalized therapy according to the stage of the disease and receptor expression with our 67Cu-based CuNeoTM component.
AlphaFlareTM targets cell adhesion receptors, so called integrins, which mediate attachment of cells to other cells or matrix proteins as well as traction of the cell during movement. These receptors are overexpressed significantly in cells during the process of tumorigenesis, tumour progression and metastasis formation and are often associated with a poor prognosis. They are markers for aggressive forms of malignancies such as pancreatic cancer, lung cancer and breast cancer. Diagnostic imaging with AlphaFlareTM’s 61Cu-component allows for the early detection of nodal and distant metastases (correct staging), enabling the most optimal therapy according to the stage of the disease and receptor expression with our 67Cu-based AlphaFlareTM component.
Neuroendocrine tumours (NETs) are rare tumours that develop in cells of the neuroendocrine system. Spread throughout the body, neuroendocrine cells can receive neuronal input like nerve cells (neurons) and, as a consequence of this input, produce and release hormones like cells of the endocrine system (endocrine cells). They are mainly found scattered in the gastrointestinal (GI) tract (including the small intestine, rectum, stomach, colon, esophagus, and appendix), the gallbladder, the pancreas (islet cells) and the thyroid (C cells). NETs are difficult to detect and are usually found at an advanced stage. Like prostate cancer, the survival rate significantly drops the more advanced or metastasised the tumor is (5-year survival for metastatic pancreatic NETs: 24 %) Our TraceNETTM program targets somatostatin receptors, which are a clinically validated NET cell marker. Our 61Cu-based TraceNETTM diagnostic component is highly precise and enables a technique called delayed imaging, where even smallest tumours can be detected early. Based on these imaging data, our 67Cu-based TraceNETTM therapeutic can enable targeted treatment with an improved safety and efficacy profile and reduced radiation burden for the patient.
1 in 8 men will be diagnosed with prostate cancer during their lifetime; 6 out of 10 cases are diagnosed in men 65 or older. The 5-year survival rate for local/regional cancer is 100% but drops drastically to 31% for metastatic cancer. Expression of the Prostate-Specific Membrane Antigen (PSMA) is up to 80 times higher in almost all prostate carcinoma tumours compared to healthy cells. NuriProTM binds specifically to PSMA, enabling precise diagnosis and targeted treatment. Our 61Cu-based NuriProTM diagnostic component enables a technique called delayed imaging, where even smallest metastases can be detected. Based on these imaging data, our 67Cu-based NuriProTM therapeutic can enable targeted treatment with an improved safety and efficacy profile and reduced radiation burden for the patient.
AlphaFlareTM targets cell adhesion receptors, so called integrins, which mediate attachment of cells to other cells or matrix proteins as well as traction of the cell during movement. These receptors are overexpressed significantly in cells during the process of tumorigenesis, tumour progression and metastasis formation and are often associated with a poor prognosis. They are markers for aggressive forms of malignancies such as pancreatic cancer, lung cancer and breast cancer. Diagnostic imaging with AlphaFlareTM’s 61Cu-component allows for the early detection of nodal and distant metastases (correct staging), enabling the most optimal therapy according to the stage of the disease and receptor expression with our 67Cu-based AlphaFlareTM component.
80 – 90% of all cancer cases are of epithelial origin, stemming from cells in the internal and external lining of the body. KaliosTM is targeting cells in the tumor microenvironment called cancer-associated fibroblasts, which are present in epithelial tumours such as breast and lung cancer and are not present in healthy tissues. Early detection of metastases in lymph nodes and crucial organs can increase the survival rate through early intervention. Unlike other tracers, our 61Cu-based KaliosTM diagnostic component can be used effectively in staging to detect nodal metastases in the liver and peritoneum.
Our Copper-based Technology
Do you want to learn more about our CuTraceTM technology platform that fuels our pipeline? Click here.
Diagnostic Nuclide
Makes tumors and metastases visible
Therapeutic Nuclide
Destroys tumors and metastases